The HIV-1 envelope glycoprotein transmembrane subunit, gp41, mediates the fusion of viral and target cell membranes. The 2 helical regions in the ectodomain of gp41, the N-helix and the C-helix, form a helical bundle complex that has been suggested as a fusion-active conformation. Previously, an enzyme-linked immunosorbent assay (ELISA) method had been established to measure the interaction of 2 helical regions of gp41. In this study, the ELISA method was modified to apply highthroughput screening (HTS) of an organic compound library. A few compounds had been identified to prevent the interaction between 2 helical regions of gp41, and they were further shown to inhibit the gp41-mediated viral infection. In addition, they specifically quenched the fluorescence of tryptophan in the N-helix region, indicating that these compounds bound to the Nhelix rather than the C-helix of gp41. These results suggested that this assay method targeting gp41 could be used for HTS of HIV fusion inhibitors. (Journal of Biomolecular Screening 2005:13-19) 
INTRODUCTION
T HE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) enters cells by the membrane fusion process, mediated by the viral envelope glycoproteins gp120/41. 1 During the infection process, the surface subunit, gp120, binds to CD4 and a chemokine receptor on the surface of the T cell, [2] [3] [4] and these interactions cause a conformational change of the transmembrane subunit, gp41, from a native (nonfusogenic) to a fusion-active (fusogenic) state. 5 Activated gp41 triggers the membrane fusion between the virus and the target cell during infection, and the control of this fusion activation process is of great interest for the development of novel HIV-1 inhibitors. Various domains in the extracellular region of gp41 have been implicated in the fusion process. The fusion peptide region, located at the amino terminus of gp41, initiates the fusion process by insertion and disruption of the target membrane. 6, 7 Then, the first helical region (N-helix) following the fusion peptide forms a trimeric coiled-coil structure, [8] [9] [10] and the second helical region (Chelix), located at the C-terminus of the N-helix, has a tendency to interact with the N-helix of gp41. [11] [12] [13] These interactions result in a 6-helical bundle complex, in which 3 N-helices form a central coiled-coil trimer, and 3 C-helices bind to the hydrophobic grooves on the surface of the coiled coil in an antiparallel direction. 14, 15 Formation of this stable helix bundle structure is assumed to provide a driving force to juxtapose 2 membranes for the fusion event. 14, 15 Synthetic peptides representing the C-helix have been shown to effectively inhibit the fusion activity of gp41 12, 13 by binding to the N-helix of gp41 and preventing the formation of fusion-active conformation of gp41. [16] [17] [18] In a clinical trial, the T20 peptide representing residues 600 to 637 of gp41 lowered the level of HIV in infective individuals, 19 suggesting that the coiled-coil trimer is a potential target for the development of anti-HIV therapeutics. Small chemical compounds that inhibited the fusion activity of gp41 have also been reported. A triterpene derived from betulinic acid (RPR103611) inhibited the infectivity of several HIV-1 strains in submicromolar concentration, 20 and it was shown to interfere with the interaction between gp41 and gp120. 21 Another type of small-molecule inhibitor had been derived by a molecular docking of existing compounds to the hydrophobic cavity located on the hydrophobic groove of the trimeric coiled coil. Two structurally related compounds identified by the molecular docking approach, ADS-J1 and ADS-J2, were shown to inhibit the membrane fusion mediated by gp41 at micromolar concentrations. 22 Recently, we have shown that 2 chimera proteins containing the N-or C-helices of gp41 have bound to each other, 23 and we also established an enzyme-linked immunosorbent assay (ELISA) system that can measure the interaction between the N-and C-helices. 13, 23 In this report, we have modified the ELISA method, show-ing that the modified ELISA method could be used for highthroughput screening (HTS) of organic compounds that can inhibit gp41. After screening 8560 compounds, a few compounds were identified to prevent the interaction of N-and C-helices of gp41. These compounds also blocked the infection of HIV-1 BaL /MuLV pseudotypes into HOS-CD4-CCR5 cells, suggesting that the assay method can be used to screen chemical compounds with anti-gp41 activity.
MATERIALS AND METHODS

Materials
The DIVERSet ™ (ChemBridge Corporation, England) chemical library containing 8560 unique compounds was used in the screening process. Fluorescein, fluoresceinamine, and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were purchased from Sigma (St. Louis, MO, USA). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco/BRL (Gaithersburg, MD, USA).
Preparation of proteins
The thioredoxin fused with the N-helix of gp41 (residues 545-595) and the glutathione S-transferase fused with the C-helix of gp41 (residues 600-668) were prepared as previously described 23 and named Trx-N and GST-C, respectively (Fig. 1A) . The GST-C was further labeled with horseradish peroxidase (HRP), using EZ-Link ™ activated peroxidase (Pierce, Rockford, IL, USA) to produce HRP-labeled GST-C (HRP-GST-C). The N38 peptide (553-590 amino acids of gp41) was prepared using an Fmoc (9fluorenylmethoxycarbonyl) strategy, 23 and the C51 peptide (618-668 amino acids of gp41) was prepared from limited proteolysis of the ectodomain of gp41, as previously described. 23 
HTS method of the gp41 inhibitory compounds
The screening method exploited the interaction of 2 helical regions of gp41. Thus, HRP-GST-C bound to the immobilized Trx-N on the bottom of the plate could be detected by measuring the activity of HRP ( Fig. 1B ). Any compound that would block the interaction between the 2 helical regions of gp41 reduced the amount of the surface-bound HRP-GST-C. The ELISA method for measuring the interaction between the N-and C-helices of gp41, described previously, was used with a little modification. 23 Briefly, 0.2 µg of the Trx-N in 60 µL of 10 mM Tris-HCl (pH 8.0) was attached to the surface of the 96-well plate by incubation overnight at 4°C. Then, the surface of the plate was blocked with 0.5% skim milk, and unbound Trx-N was washed with phosphate-buffered saline-Tween (PBS-T; 100 mM sodium phosphate, 150 mM sodium chloride, 0.2% Tween-20, pH 7.0). The tested compound, in 30 µL of a PBS buffer (100 mM sodium phosphate, 150 mM sodium chloride, pH 7.0), was applied to the Trx-N-coated plate and incubated at room temperature for 20 min, and then 0.12 µg of the HRP-GST-C in 30 µL of PBS was applied. After incubation at room temperature for 1 h, unbound HRP-GST-C was thoroughly washed out with PBS-T. The amount of bound GST-C was measured by adding a color-generating HRP substrate (0.1% ophenylenediamine dihydrochloride, 1× Stable Peroxide Substrate Buffer; Pierce, Rockford, IL, USA). The reaction was terminated by adding 60 µL of 2.5 M sulfuric acid, and absorbance at 490 nm was measured using a Spectra Max 340 spectrophotometer (Molecular Devices Corp, Ramsey, MN, USA).
Viral infection assay
Anti-HIV-1 activities of the chemical compounds were assayed by observing the inhibition of the HIV-1 BaL /MuLV pseudotype infection into HOS-CD4-CCR5 cells in the presence of various concentrations of chemical compounds. 24 When the pseudotype in- fects the target cells, the infected cells express β-galactosidase in the nucleus because the MFG-nls-LacZ RNA contains a MuLVderived packaging signal, a nuclear localizing signal, and a βgalactosidase gene packaged in the pseudotype viral particles. 25 The stock of chemical compounds was prepared at 10 mg/mL in DMSO. The stock was diluted in media to the concentrations required for the experiment. The compound was added to the wells of a 96-well plate containing 3 × 10 4 HOS-CD4-CCR5 cells, and 300 to 500 infectious units (IU)/well of the pseudotypes were then added. After 36 to 40 h of culture, the infected cells were observed by 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) staining, as described previously. 24 The toxicity of the tested compounds was determined by measuring the viability of the treated cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, as previously described. 26 
Fluorescence
The binding of the screened inhibitors on N-or C-helices of gp41 was examined by measuring their quenching effect on tryptophan fluorescence. About 1.0 µM of Trx-N, Trx, or GST-C was mixed with various concentrations of inhibitors, and the intensities of tryptophan fluorescence were monitored with an excitation wavelength of 280 nm and an emission wavelength of 350 nm, using a Luminescence spectrometer LS50B (PerkinElmer, Boston, MA, USA. The ratio of fluorescence intensities in the absence (F 0 ) or presence (F) of inhibitors was measured at various concentrations of the inhibitor.
RESULTS
Assay optimization and validation
The crystal structure of the core region in the extracellular domain of gp41 indicated that N-and C-helices bind to each other to form a stable helical bundle structure. 14, 15 To measure the interaction of N-and C-helices of gp41, we constructed 2 chimera proteins of Trx and GST, which display the N-and C-helix regions of gp41, respectively. Two helical regions in gp41, Trx-N, GST-C, C51, and N38, along with their amino acid sequences, are represented in Figure 1A . Previously, it was shown that Trx-N formed a trimer in solution and that GST-C interacted with the immobilized Trx-N. 23 HRP-GST-C also effectively bound to a surface immobilized with Trx-N in a dose-dependent way ( Fig. 2A) . The specific binding of HRP-GST-C to Trx-N is indistinguishable from the binding property of GST-C to Trx-N. 23 Previously, a 51-mer peptide representing residues 618 to 668 of gp41 (C51 peptide) was shown to bind to the N-helix and block the cell fusion mediated by Env of HIV-and CD4-presenting cells. 23 In the presence of 0.3 µg/ mL of the C51 peptide, the amount of bound HRP-coupled GST-C was reduced to 50%, and higher concentrations of the C51 peptide further prevented the binding of HRP-GST-C (Fig. 2B ). This result indicated that an inhibitor of the interaction between N-and C-helices could be screened with the in vitro assay method. The chimera proteins were used for the assay method because the Trx and GST domains increased the expression level and solubility of the chimera proteins without interfering with the interaction between the N-and C-helices of gp41 (data not shown). With this assay method, a screening of the chemical compound library was performed in 96-well plates. To check the quality of this assay for HTS, the Z′ factor was calculated 27 and plotted against the plate number in Figure 3 . The calculated Z′ factor was between 0.6 and 0.9, with an average Z′ value of 0.893, indicating that the screening method had high sensitivity and was valid for HTS. 27 
Screening of HIV-1 gp41 Inhibitor
Anti-gp41 compounds
To search for potent anti-gp41 activities, we screened a chemical library consisting of 8560 compounds using the established assay method depicted in Figure 1B . The chemical library used in this study, DIVERSet ™ , consists of biologically druglike small molecules that were selected based on their structural diversity, with their purity confirmed by nuclear magnetic resonance (NMR)/mass spectrometry analysis. From the primary screening, several compounds inhibited more than 50% of the binding activity of HRP-GST-C on Trx-N at 50 µg/mL. The IC 50 values of these compounds were measured, and the compounds with IC 50 values lower than 20 µM were selected for further examination in the cell fusion assay. Among them, 2 fluorescein derivatives, KY001 and KY002 (Fig. 4) , had significant inhibitory activities in the assay system (Fig. 5A) . In contrast, fluorescein and fluoresceinamine, which contain a common structural moiety with KY001 and KY002, failed to show inhibitory activities up to 300 µM (Table 1) .
Anti-HIV-1 activity of identified compounds
The compounds selected from the screening of the library were further tested for their inhibitory activity of HIV-1 infection 24 and cytotoxicity. 26 All of the compounds that had anti-gp41 activities also prevented the HIV-1 BaL infection in the HOS-CD4-CCR5 cells ( Table 1) . Among them, KY001 and KY002 effectively inhibited the HIV-1 infection, with IC 50 values of 65 and 30 µM, respectively (Fig. 5B ). On the contrary, fluorescein and fluoresceinamine could not prevent viral infection in the highest concentration of the tested compounds ( Table 1 ). All tested compounds did not show the cytotoxicity in the range of the tested concentrations using the MTT assay ( Fig. 5C ). At 300 µM or higher concentration, however, KY001 and KY002 showed cytotoxicity (data not shown). It is noticeable that the compounds that showed inhibitory activity against the viral infection to the target cells also inhibited the interaction of Trx-N and GST-C. The correlation of inhibitory activity from in vivo and in vitro assays indicated that the in vitro assay system could be applied for fast screening of gp41 inhibitors.
Determination of the binding partner of the screened compounds by quenching tryptophan fluorescence
The screened compounds that inhibit the interaction between the N-and C-helices of gp41 could bind either helix region. To determine the binding site of the isolated compounds, we examined the quenching effects of KY001 and KY002 on the tryptophan flu- orescence of Trx-N and GST-C. These compounds did not interfere with the intensity or peak shape of the fluorescence from free tryptophan up to 100 µM (data not shown). However, they significantly reduced the fluorescence intensity of the tryptophan residues of Trx-N within 30 µM (Fig. 6) . At a concentration of 2 µM of KY001, which is twice as high as the concentration of Trx-N, they reduced the intensity by less than 50%, and at 10 times higher concentration (10 µM), about 90% of the fluorescence intensity had been reduced. In contrast, they hardly affected the tryptophan fluo- rescence from Trx or GST-C up to 30 µM (Fig. 6A ). Likewise, KY002 showed an N-helix specific quenching effect on Trx-N. Interestingly, KY002 showed a considerable quenching effect on GST-C. However, this effect was due to nonspecific interaction with the GST domain because its quenching efficiency on GST was identical to that of GST-C (Fig. 6B) . These results indicate that the screened compounds bound to the N-helix rather than the Trx domain or GST-C.
DISCUSSION
Validation of assay method
Elucidating the core structure of gp41, which mediates the key process of HIV infection, provides a new target for an anti-HIV drug. [16] [17] [18] [19] The 2 helical regions in the core region of the gp41 bound to each other to form a stable helical bundle complex, 14, 15 and such interaction was exploited to develop an in vitro assay system. 23 In this study, we tested the assay system for the identification of compounds that could prevent the formation of a fusion-competent structure of gp41 and a membrane fusion process. The isolated compounds also showed inhibitory activities against a gp41mediated viral infection process, although the IC 50 values were 3 to 10 times higher than those from an in vitro assay method ( Table 1 ). The requirement of having a higher concentration of inhibitors in the viral infection assay might be due to the low accessibility of the inhibitors to the targeting sites or the higher effective concentration of the competing C-helix, which connected to the N-helix region in the same polypeptide in the viral infection assay. The consistency of the inhibitory activities of the identified compounds in both assay systems indicated that the interaction between the 2 helical regions of gp41 could be employed for the identification of novel anti-HIV agents. We also observed that some of the compounds that showed inhibitory activities on the ELISA system failed to prevent gp41-mediated cell fusion (data not shown).
Characteristics of the screened anti-gp41 compounds
The anti-gp41 compounds identified from the screening of a chemical library showed distinct structural features. Two fluorescein derivatives, KY001 and KY002, showed relatively high anti-gp41 activity. KY001, known as eosin Y, has bromesubstitutions adjacent to the hydroxyl and carbonyl groups of the xanthene ring structure of fluorescein, and KY002 has a chlorinated triazine ring at the amine group of fluoresceinamine. These modifications seem to be important for anti-gp41 activity: fluorescein and fluoresceinamine that lack such modifications failed to show inhibitory activity up to the concentration of about 300 µM ( Table 1 ). The specific quenching of tryptophan fluorescence of Trx-N by KY001 and KY002 indicated that these compounds bind to the N-helix region. Structural studies have indicated that the coiled-coil trimer of the N-helix has a relatively hydrophobic surface as well as a distinct hydrophobic pocket. 14, 15 It is assumed that binding of the isolated compounds to the transiently exposed N-helix coiled coil may prevent the formation of a fusion-active structure of gp41 (Fig. 7) . In conclusion, the ELISAbased assay characterized in this study is a simple and economic method for screening a chemical compound library for the identifi-Journal of Biomolecular Screening 10(1); 2005 --FIG. 7. The possible targeting site of the isolated gp41 inhibitors. For the fusion process, the following are required: insertion of the fusion peptide into the target cell membrane and formation of stable helical bundle by the N-and C-helical regions of gp41. The N-helix coiled coil of gp41 exposed during the fusion process is assumed a target for the isolated inhibitors. Tight binding of the inhibitors to the N-helix coiled coil would prevent the formation of the fusogenic conformation. cation of a gp41 inhibitor. This system is expandable to automatic operation using a 384-well plate format.
